Proactive Investors - Run By Investors For Investors

Verona Pharma reports positive results from Phase II study of lead drug

Verona Pharma reports positive results from Phase II study of lead drug

Biotech junior Verona Pharma (LON:VRP) announced positive results from a further Phase II study of its lead drug RPL554 for the treatment of asthma, which broker Evolution said would boost its licensing package.

The study tested the duration of the drug’s bronchodilator action, which increases airflow to the lungs, by administering repeated doses of the drug to patients with mild asthma. Twelve patients were treated with daily doses of RPL554 for six days.

The trial successfully demonstrated that RPL554 had sustained bronchodilator actions throughout the treatment period with no accumulation of the drug in plasma. No safety issues were observed apart from a minor increase in heart rate at the last day of treatment.

“The clinical studies performed so far with RPL554 have defined the actions of our drug in terms of doses that are safe and produce a clear and unequivocal bronchodilator effect,” said chief executive of Verona Pharma Michael Walker.

“This bronchodilator effect is of value in the treatment of asthma, and possibly chronic obstructive pulmonary disease (COPD).”

Verona is now planning another trial to test the drug’s anti-inflammatory effects, expecting it to start later this year.

Should the next trial be successful, RPL554 will become the first of a new class of drugs that treat both asthma and COPD, which Verona called “common diseases with significant markets that are in need of new drugs”.

In the meantime, Verona continues its effort to license RPL554.

Broker Evolution welcomed the update, saying that the trial results have bolstered the RPL554 licensing package.

“While important in its own right this result paves the way to design further supplemental clinical studies including one that will more definitively explore the drug’s anti-inflammatory effect,” said EVO analyst Simon Conway.

Conway currently rates Verona as a “buy” with a target price of 30 pence, a significant premium to the stock’s current price of 8.75 pence. Verona has a market cap of £21 million.

View full VRP profile View Profile

Verona Pharma Timeline

June 20 2016
November 26 2010

Related Articles

scientist in lab
February 25 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
scientist in a lab
April 12 2019
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months
man with erectile dysfunction
June 17 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use